Ocera secures $20 million debt facility from Oxford Finance and Silicon Valley Bank
Ocera Therapeutics announced that it secured a $20 million debt facility from Oxford Finance and Silicon Valley Bank. Ocera intends to use the additional capital to support ongoing development of the company’s novel molecule OCR-002 to treat acute and chronic patients with hepatic encephalopathy. July 30, 2015